C4X Discovery Holdings plc
(“C4XD”, “C4X Discovery” or the “Company”)
Half-year results for the six months ended 31 January 2020
Continued progress across Drug Discovery portfolio
29 April 2020 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces its interim results for the six months ended 31 January 2020.
Dr Clive Dix, CEO of C4X Discovery, commented: “We continue to progress our portfolio, with our inflammatory programmes generating significant advances. In particular, our lead IL-17 oral compound has progressed into Lead Optimisation following recent data demonstrating inhibition of inflammation following oral dosing in pre-clinical disease models. Our collaborations with LifeArc and Horizon Discovery, along with results from our Taxonomy3® platform, provide compelling insights as the next wave of potential candidates continue to advance. As a result of discussions with potential partners for our NRF-2 activator programme, we intend to enhance the licensing package and add value with additional study data focused on candidate nomination, as we did with partnered programme, Orexin-1. With this enhancement of our NRF-2 programme, the licensing process timeline is difficult to predict,” Dr Dix added: “I am extremely proud that although our focus has been to ensure the safety and wellbeing of our employees they have risen to the challenges of progressing our business activities during these difficult times.”
Operational highlights:
Financial highlights:
Analyst conference call today
Dr Clive Dix, Chief Executive Officer, and members of the management team will host a webcast for analysts at 11am BST today. A copy of the final results presentation will be released later this morning on the Company website at www.c4xdiscovery.com. Please contact Consilium Strategic Communications for details on C4XDiscovery@consilium-comms.com / +44 203709 5700.
C4X Discovery Holdings plc
Mo Noonan, Communications+44 (0)7876 444 977
Panmure Gordon (UK) Limited (NOMAD and Broker) +44 (0)20 7886 2500
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709 5700
C4X Discovery (C4XD) aims to create the world’s most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company’s business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294 million.
C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD’s commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.
For additional information please go to:www.c4xdiscovery.com
This website uses 'cookies' to give you the best most relevant experience. To continue you have to agree to our use of cookies policy and how and why we use cookies.
You can change which cookies are set at any time and find out more about them by reading our privacy policy.